Digital Therapeutics/DTx Market
完整報告名稱與涵蓋範圍
Digital Therapeutics/DTx Market by Offering (Software, Immersive), Application (Treatment (Diabetes, CNS, CVD, Rehab), Preventive), Revenue (Subscription, Enterprise), Channel (B2B, B2C), End User (Hospitals, Payers, Employers) - Global Forecast to 2031
報告摘要
The global digital therapeutics market is projected to reach USD 35.37 billion by 2031 from USD 10.95 billion in 2026, at a CAGR of 26.4% from 2026 to 2031. The growth of the digital therapeutics market is being driven by the increasing prevalence of chronic diseases, rising demand for personalized and remote patient care, and the growing focus on improving clinical outcomes while reducing healthcare costs. Healthcare providers, payers, and employers are increasingly adopting evidence-based digital therapeutics to prevent, manage, and treat conditions such as diabetes, obesity, cardiovascular diseases, musculoskeletal disorders, insomnia, and mental health disorders through clinically validated software interventions. Furthermore, regulatory and reimbursement support for digital health solutions continues to strengthen. In March 2025, the European Health Data Space (EHDS) Regulation entered into force, establishing a harmonized framework for the secure exchange and secondary use of electronic health data across the European Union, which is expected to facilitate the integration and scalability of digital therapeutics. In addition, continued advances in artificial intelligence (AI), remote patient monitoring, wearable technologies, and interoperable digital health infrastructure are enhancing the personalization, accessibility, and effectiveness of digital therapeutics while supporting value-based healthcare delivery. However, market growth may be constrained by fragmented reimbursement policies across countries, evolving regulatory requirements, concerns regarding data privacy and cybersecurity, limited awareness among healthcare professionals, and the need for robust clinical and real-world evidence to demonstrate long-term therapeutic and economic value.
“In 2025, the hospitals segment accounted for the largest share of the digital therapeutics market, by end user.”
By end user, hospitals accounted for the largest share of the digital therapeutics market in 2025. Their leading position is driven by the increasing integration of digital therapeutics into multidisciplinary care pathways for chronic disease management, mental health, rehabilitation, and post-acute care. Hospitals are adopting these solutions to complement conventional therapies, improve patient engagement, support continuous remote monitoring, and enhance treatment adherence beyond inpatient settings. The growing emphasis on value-based care, reducing hospital readmissions, and delivering personalized, data-driven interventions has further accelerated the deployment of digital therapeutics across hospital networks. In addition, the availability of integrated digital health infrastructure, established clinical workflows, and stronger collaboration with technology developers and healthcare providers has enabled hospitals to effectively implement evidence-based digital therapeutic solutions at scale. As healthcare systems continue to prioritize connected care models and long-term disease management, hospitals have maintained their position as the largest end-user segment in the digital therapeutics market.
“The B2C segment, by sales channel, is expected to register the fastest growth during the forecast period.”
By sales channel, the B2C (business-to-consumer) segment is expected to be the fastest-growing segment in the digital therapeutics market during the forecast period. This growth is driven by increasing consumer awareness of digital health solutions, rising demand for convenient self-management tools, and growing acceptance of preventive and wellness-focused care. Consumers are increasingly adopting digital therapeutics through mobile applications and connected devices to manage conditions such as obesity, sleep disorders, stress, anxiety, diabetes, and other lifestyle-related diseases without relying solely on traditional healthcare settings. The rapid expansion of smartphone penetration, wearable health technologies, and subscription-based digital health platforms has made these solutions more accessible and affordable for a broader population. Additionally, advancements in artificial intelligence, personalized behavioral coaching, and real-time health insights are improving user engagement and long-term adherence, while direct-to-consumer marketing strategies and expanding digital distribution channels are further accelerating the adoption of B2C digital therapeutics throughout the forecast period.
“Asia Pacific to witness the highest growth rate during the forecast period.”
The Asia Pacific region is projected to register the highest growth rate in the digital therapeutics market during the forecast period. This growth is driven by the rising prevalence of chronic diseases, rapid healthcare digitalization, increasing smartphone adoption, and supportive government initiatives promoting digital health infrastructure across the region. Countries such as China, Japan, India, South Korea, Singapore, and Australia are expanding investments in telehealth, remote patient monitoring, artificial intelligence (AI)-enabled healthcare, and digital disease management to improve healthcare accessibility and address the growing burden of diabetes, cardiovascular diseases, obesity, and mental health disorders. Furthermore, the increasing presence of digital health startups, expanding collaborations between healthcare providers and technology companies, and growing reimbursement support for digital health solutions are accelerating the adoption of digital therapeutics across the region. Recent industry developments further reinforce this momentum; in February 2024, TruDoc Healthcare acquired Wellthy Therapeutics, one of Asia’s leading digital therapeutics companies, to strengthen its digital healthcare capabilities across the GCC region while expanding into India, combining Wellthy's clinically validated digital therapeutics platform with TruDoc's virtual primary care and remote healthcare services. This acquisition highlights the increasing strategic investments in digital therapeutics and reinforces Asia Pacific's position as a key hub for innovation and commercialization in digital health.
The breakdown of primary participants is as mentioned below:
• By Company Type - Tier 1: 34%, Tier 2: 46%, and Tier 3: 20%
• By Designation - C-level: 35%, Director-level: 25%, and Others: 40%
• By Region - North America: 30%, Europe: 45%, Asia Pacific: 20%, Middle East & Africa: 3%, and Latin America: 2%
Key Players in the Digital Therapeutics Market
The key players functioning in the digital therapeutics market include Teladoc Health, Inc. (US), Noom, Inc. (US), Omada Health Inc. (US), Hinge Health, Inc. (US), DarioHealth Corp. (US), and Sword Health, Inc. (Portugal).
Research Coverage:
This research report categorizes the digital therapeutics market by offering (software/platforms, therapeutic programs, immersive & interface-based therapeutics), product type (prescription digital therapeutics, non-prescription digital therapeutics), application (treatment & care-related applications, preventive applications), revenue model (subscription-based model, licensing (enterprise/SAAS) model, outcome-/value-based model), sales channel (B2B sales channel, B2C sales channel), end user (healthcare provider, payers, employers, patients/individuals, other end users), and region (North America, Europe, Asia Pacific, Latin America, and Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the digital therapeutics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions and services, key strategies (contracts, partnerships, agreements, product & service launches, mergers, and acquisitions), and recent developments associated with the digital therapeutics market. Competitive analysis of upcoming startups in the digital therapeutics market ecosystem is covered in this report.
Reasons to Buy the Report
This report will enrich established firms and new entrants/smaller firms to gauge the market's pulse, which, in turn, would help them gain a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.
This report provides insights on:
Analysis of key drivers (rising prevalence of chronic and behavioral health conditions, shift toward value-based and patient-centered care, expansion of smartphone adoption and digital health infrastructure, growing clinical evidence and regulatory recognition), restraints (limited reimbursement and inconsistent payment pathways, regulatory complexity and evolving approval frameworks), opportunities (expansion into new therapeutic areas, integration with AI and personalized medicine, increasing partnerships with pharmaceutical and healthcare organizations), and challenges (sustaining long-term patient engagement and adherence, demonstrating long-term clinical and economic value) influencing the growth of the digital therapeutics market.
Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the digital therapeutics market.
Market Development: Comprehensive information on the lucrative emerging markets, offering, product type, application, revenue model, sales channel, end user, and region.
Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the digital therapeutics market.
Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the digital therapeutics market like Teladoc Health, Inc. (US), Noom, Inc. (US), Omada Health Inc. (US), Hinge Health, Inc. (US), DarioHealth Corp. (US), Sword Health, Inc. (Portugal).
授權報價
| Single User Licence | $4,950 USD |
| Multi User Licence | $6,650 USD |
| Corporate User Licence | $8,150 USD |
| Global User Licence | $10,000 USD |
目錄 Table of Contents
1 INTRODUCTION 36
1.1 STUDY OBJECTIVES 36
1.2 MARKET DEFINITION 36
1.3 STUDY SCOPE 37
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 37
1.3.2 INCLUSIONS & EXCLUSIONS 38
1.3.3 YEARS CONSIDERED 39
1.4 CURRENCY CONSIDERED 39
1.5 LIMITATIONS 40
1.6 STAKEHOLDERS 40
1.7 SUMMARY OF CHANGES 41
2 EXECUTIVE SUMMARY 42
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 42
2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS 43
2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH 44
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 45
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 46
3 PREMIUM INSIGHTS 48
3.1 DIGITAL THERAPEUTICS MARKET OVERVIEW 48
3.2 DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE & COUNTRY 49
3.3 DIGITAL THERAPEUTICS MARKET: GEOGRAPHIC SNAPSHOT 49
4 MARKET OVERVIEW 50
4.1 INTRODUCTION 50
4.2 MARKET DYNAMICS 51
4.2.1 DRIVERS 51
4.2.1.1 Rising prevalence of chronic and behavioral health conditions 51
4.2.1.2 Shift toward value-based and patient-centered care 52
4.2.1.3 Expansion of smartphone adoption and digital health infrastructure 53
4.2.1.4 Growing clinical evidence and regulatory recognition 53
4.2.2 RESTRAINTS 54
4.2.2.1 Limited reimbursement and inconsistent payment pathways 54
4.2.2.2 Regulatory complexity and evolving approval frameworks 55
4.2.3 OPPORTUNITIES 55
4.2.3.1 Expansion into new therapeutic areas 55
4.2.3.2 Integration with AI and personalized medicine 56
4.2.3.3 Increasing partnerships with pharmaceutical and healthcare organizations 56
4.2.4 CHALLENGES 57
4.2.4.1 Sustaining long-term patient engagement and adherence 57
4.2.4.2 Demonstrating long-term clinical and economic value 57
4.3 UNMET NEEDS & WHITE SPACES 58
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 58
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 59
5 INDUSTRY TRENDS 61
5.1 PORTER’S FIVE FORCES ANALYSIS 61
5.1.1 BARGAINING POWER OF SUPPLIERS 62
5.1.2 BARGAINING POWER OF BUYERS 62
5.1.3 THREAT OF SUBSTITUTES 62
5.1.4 THREAT OF NEW ENTRANTS 62
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 63
5.2 MACROECONOMIC INDICATORS 63
5.2.1 INTRODUCTION 63
5.2.2 GDP TRENDS & FORECAST 63
5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY 63
5.3 VALUE CHAIN ANALYSIS 64
5.3.1 RESEARCH & PRODUCT DEVELOPMENT 65
5.3.2 DATA INPUTS & TECHNOLOGY INFRASTRUCTURE 65
5.3.3 PLATFORM DEVELOPMENT & DEPLOYMENT 65
5.3.4 DISTRIBUTION 66
5.3.5 MARKETING & SALES 66
5.3.6 POST-SALES SERVICES 66
5.4 ECOSYSTEM ANALYSIS 66
5.5 PRICING ANALYSIS 68
5.5.1 INDICATIVE PRICING FOR DIGITAL THERAPEUTICS SOLUTIONS,
BY OFFERING (2025) 68
5.5.2 INDICATIVE PRICING FOR DIGITAL THERAPEUTICS SOLUTIONS,
BY REGION (2025) 69
5.6 KEY CONFERENCES & EVENTS, 2026–2027 70
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 71
5.8 INVESTMENT & FUNDING SCENARIO 71
5.9 CASE STUDY ANALYSIS 72
5.10 IMPACT OF 2025 US TARIFFS ON DIGITAL THERAPEUTICS MARKET 74
5.10.1 INTRODUCTION 74
5.10.2 KEY TARIFF RATES 74
5.10.3 PRICE IMPACT ANALYSIS 75
5.10.4 IMPACT ON COUNTRY/REGION 76
5.10.4.1 US 76
5.10.4.2 Europe 76
5.10.4.3 Asia Pacific 76
5.10.5 IMPACT ON END-USE INDUSTRY 76
5.10.5.1 Healthcare providers 76
5.10.5.2 Payers 77
5.10.5.3 Employers 77
5.10.5.4 Patients/Individuals 77
5.10.5.5 Other end users 77
6 STRATEGIC DISRUPTIONS THROUGH TECHNOLOGY, PATENTS,
AND DIGITAL & AI ADOPTION 78
6.1 KEY EMERGING TECHNOLOGIES 78
6.1.1 SOFTWARE AS A MEDICAL DEVICE (SAMD) 78
6.1.2 MOBILE HEALTH (MHEALTH) APPLICATIONS 78
6.1.3 ARTIFICIAL INTELLIGENCE (AI) & MACHINE LEARNING (ML) 79
6.2 COMPLEMENTARY TECHNOLOGIES 79
6.2.1 REMOTE PATIENT MONITORING (RPM) 79
6.2.2 INTERNET OF MEDICAL THINGS (IOMT) 80
6.3 ADJACENT TECHNOLOGIES 80
6.3.1 ELECTRONIC HEALTH RECORDS (EHR/EMR) 80
6.3.2 DIGITAL DIAGNOSTICS 80
6.4 TECHNOLOGY/PRODUCT ROADMAP 80
6.5 PATENT ANALYSIS 81
6.5.1 PATENT PUBLICATION TRENDS FOR DIGITAL THERAPEUTICS MARKET 81
6.5.2 INSIGHTS: JURISDICTION & TOP APPLICANT ANALYSIS 83
6.6 FUTURE APPLICATIONS 85
6.6.1 AI-ENABLED PERSONALIZED THERAPEUTICS & CLINICAL DECISION SUPPORT 86
6.6.2 CONTINUOUS REMOTE CARE & DIGITAL HEALTH ECOSYSTEMS 86
6.6.3 DIGITAL BIOMARKER-DRIVEN PREVENTIVE & PRECISION CARE 86
6.7 IMPACT OF AI/GEN AI ON DIGITAL THERAPEUTICS MARKET 87
6.7.1 INTRODUCTION 87
6.7.2 MARKET POTENTIAL OF AI/GEN AI IN DIGITAL THERAPEUTICS MARKET 88
6.7.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION 89
6.7.3.1 AI technologies in digital therapeutics 89
6.7.4 IMPACT OF AI/GEN AI ON INTERCONNECTED & ADJACENT ECOSYSTEMS 90
6.7.4.1 Digital health & telehealth market 90
6.7.4.2 Remote patient monitoring (RPM) market 90
6.7.4.3 Electronic health records (EHR/EMR) market 91
6.7.5 USER READINESS & IMPACT ASSESSMENT 91
6.7.5.1 User readiness 91
6.7.5.1.1 User A: Healthcare providers 91
6.7.5.1.2 User B: Payers 91
6.7.5.2 Impact assessment 92
6.7.5.2.1 User A: Healthcare providers 92
6.7.5.2.1.1 Implementation 92
6.7.5.2.1.2 Impact 92
6.7.5.2.2 User B: Payers 92
6.7.5.2.2.1 Implementation 92
6.7.5.2.2.2 Impact 92
7 SUSTAINABILITY & REGULATORY LANDSCAPE 93
7.1 REGIONAL REGULATIONS & COMPLIANCE 93
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94
7.1.2 REGULATORY FRAMEWORK 97
7.1.2.1 North America 97
7.1.2.2 Europe 97
7.1.2.3 Asia Pacific 98
7.1.2.4 Latin America 98
7.1.2.5 Middle East & Africa 99
7.1.3 INDUSTRY STANDARDS 99
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 101
8.1 INTRODUCTION 101
8.2 DECISION-MAKING PROCESS 101
8.3 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 101
8.3.1 KEY STAKEHOLDERS IN BUYING PROCESS 102
8.3.2 BUYING CRITERIA 102
8.4 ADOPTION BARRIERS & INTERNAL CHALLENGES 103
8.5 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 104
8.5.1 UNMET NEEDS 104
8.5.2 END-USER EXPECTATIONS 105
8.6 MARKET PROFITABILITY 106
9 DIGITAL THERAPEUTICS MARKET, BY OFFERING 108
9.1 INTRODUCTION 109
9.2 SOFTWARE/PLATFORMS 109
9.2.1 AI-DRIVEN PLATFORM ARCHITECTURES AND EXPANDING REGULATORY PATHWAYS TO DRIVE MARKET EXPANSION 109
9.3 THERAPEUTIC PROGRAMS 111
9.3.1 EXPANDING FDA CLEARANCES ACROSS NEW INDICATIONS AND MATURING REIMBURSEMENT CODES TO DRIVE PROGRAM ADOPTION 111
9.4 IMMERSIVE & INTERFACE-BASED THERAPEUTICS 112
9.4.1 GROWING CLINICAL EVIDENCE AND NEW REIMBURSEMENT CODES FOR
VR-DELIVERED CARE TO DRIVE SEGMENT GROWTH 112
10 DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE 114
10.1 INTRODUCTION 115
10.2 PRESCRIPTION DIGITAL THERAPEUTICS 115
10.2.1 REGULATORY APPROVALS AND GROWING CLINICAL VALIDATION TO ACCELERATE ADOPTION OF PRESCRIPTION DIGITAL THERAPEUTICS 115
10.3 NON-PRESCRIPTION DIGITAL THERAPEUTICS 116
10.3.1 INCREASING CONSUMER ACCESSIBILITY AND DIGITAL HEALTH ADOPTION TO ACCELERATE GROWTH OF NON-PRESCRIPTION DIGITAL THERAPEUTICS 116
11 DIGITAL THERAPEUTICS MARKET, BY APPLICATION 118
11.1 INTRODUCTION 119
11.2 TREATMENT & CARE-RELATED APPLICATIONS 119
11.2.1 DIABETES 121
11.2.1.1 Rising global diabetes burden and connected digital care to accelerate adoption of digital therapeutics 121
11.2.2 CENTRAL NERVOUS SYSTEM (CNS) DISORDERS 122
11.2.2.1 Rising mental health burden and AI-enabled behavioral care to accelerate adoption of digital therapeutics for CNS disorders 122
11.2.3 SMOKING CESSATION 123
11.2.3.1 Increasing tobacco control initiatives and behavioral interventions to boost adoption 123
11.2.4 CHRONIC RESPIRATORY DISEASES 124
11.2.4.1 Rising burden of chronic respiratory conditions and remote disease management to fuel growth 124
11.2.5 MUSCULOSKELETAL DISORDERS 125
11.2.5.1 Rising burden of musculoskeletal conditions and AI-enabled rehabilitation to support market growth 125
11.2.6 CARDIOVASCULAR DISORDERS 126
11.2.6.1 Growing cardiovascular disease burden and remote cardiac care to contribute to market growth 126
11.2.7 MEDICATION ADHERENCE 127
11.2.7.1 Growing need to improve treatment compliance and long-term outcomes to drive growth 127
11.2.8 SLEEP DISORDERS 128
11.2.8.1 Rising prevalence of sleep disorders and connected sleep care to accelerate adoption of digital therapeutics 128
11.2.9 REHABILITATION & PATIENT CARE 129
11.2.9.1 Digital rehabilitation platforms to transform recovery beyond traditional clinical settings 129
11.2.10 SUBSTANCE USE DISORDERS & ADDICTION MANAGEMENT 130
11.2.10.1 Digital therapeutics to expand access to evidence-based addiction treatment and long-term recovery support 130
11.2.11 OTHER TREATMENT & CARE-RELATED APPLICATIONS 131
11.3 PREVENTIVE APPLICATIONS 132
11.3.1 PREDIABETES 134
11.3.1.1 Early risk identification and lifestyle intervention to drive adoption of digital therapeutics for prediabetes 134
11.3.2 OBESITY & WEIGHT MANAGEMENT 135
11.3.2.1 Digital therapeutics to complement GLP-1 therapies and enable sustainable weight management 135
11.3.3 NUTRITION & LIFESTYLE MANAGEMENT 136
11.3.3.1 Personalized nutrition and lifestyle coaching to expand role of digital therapeutics in preventive healthcare 136
11.3.4 OTHER PREVENTIVE APPLICATIONS 137
12 DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL 138
12.1 INTRODUCTION 139
12.2 SUBSCRIPTION-BASED MODELS 139
12.2.1 CONTINUOUS CARE DELIVERY AND RECURRING PATIENT ENGAGEMENT TO STRENGTHEN ADOPTION 139
12.3 LICENSING (ENTERPRISE/SAAS) MODELS 140
12.3.1 ENTERPRISE ADOPTION AND SCALABLE CLOUD DEPLOYMENTS TO DRIVE GROWTH OF LICENSING (ENTERPRISE/SAAS) MODELS 140
12.4 OUTCOME-/VALUE-BASED MODELS 141
12.4.1 GROWING SHIFT TOWARD PERFORMANCE-BASED REIMBURSEMENT TO DRIVE ADOPTION OF OUTCOME-/VALUE-BASED MODELS 141
13 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL 143
13.1 INTRODUCTION 144
13.2 B2B SALES CHANNELS 144
13.2.1 HEALTHCARE ECOSYSTEM PARTNERSHIPS AND REIMBURSEMENT EXPANSION TO DRIVE B2B LEADERSHIP IN DIGITAL THERAPEUTICS 144
13.3 B2C SALES CHANNELS 145
13.3.1 CONSUMER-CENTRIC DIGITAL HEALTH ADOPTION AND PREVENTIVE CARE TRENDS TO ACCELERATE B2C GROWTH 145
14 DIGITAL THERAPEUTICS MARKET, BY END USER 147
14.1 INTRODUCTION 148
14.2 HEALTHCARE PROVIDERS 148
14.2.1 HOSPITALS 149
14.2.1.1 Expanding digital care delivery to drive hospital adoption of digital therapeutics 149
14.2.2 SPECIALTY CLINICS 150
14.2.2.1 Condition-specific care delivery to accelerate digital therapeutics adoption in specialty clinics 150
14.2.3 DIAGNOSTIC & REHABILITATION CENTERS 151
14.2.3.1 Digital rehabilitation and outcome-focused care to drive adoption in diagnostic & rehabilitation centers 151
14.2.4 OTHER HEALTHCARE PROVIDERS 152
14.3 HEALTHCARE PAYERS 153
14.3.1 PUBLIC PAYERS 154
14.3.1.1 Government-led digital health programs to expand role of digital therapeutics in public healthcare 154
14.3.2 PRIVATE PAYERS 155
14.3.2.1 Outcome-based insurance models and employer health strategies to boost digital therapeutics adoption among private payers 155
14.4 EMPLOYERS 156
14.4.1 GROWING EMPHASIS ON PREVENTIVE HEALTHCARE AND VALUE-BASED EMPLOYEE BENEFITS TO ACCELERATE ADOPTION ACROSS EMPLOYER SEGMENT 156
14.5 PATIENTS/INDIVIDUALS 157
14.5.1 INCREASING PREFERENCE FOR SELF-MANAGED AND PREVENTIVE HEALTHCARE TO DRIVE ADOPTION IN SEGMENT 157
14.6 OTHER END USERS 158
15 DIGITAL THERAPEUTICS MARKET, BY REGION 160
15.1 INTRODUCTION 161
15.2 NORTH AMERICA 161
15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 162
15.2.2 US 167
15.2.2.1 Expanding reimbursement, AI-powered care, and chronic disease management to drive digital therapeutics adoption 167
15.2.3 CANADA 172
15.2.3.1 Digital health expansion and public healthcare innovation to support digital therapeutics adoption 172
15.3 EUROPE 176
15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 177
15.3.2 GERMANY 181
15.3.2.1 Strong digital health ecosystem and favorable reimbursement to drive digital therapeutics adoption 181
15.3.3 FRANCE 186
15.3.3.1 Digital therapeutics access and reimbursement pathway development to boost market expansion 186
15.3.4 UK 190
15.3.4.1 NHS digital transformation and strong regulatory support to accelerate adoption 190
15.3.5 ITALY 195
15.3.5.1 Healthcare digitalization and chronic disease burden to create growth opportunities for digital therapeutics 195
15.3.6 SPAIN 199
15.3.6.1 Healthcare digitalization and telehealth expansion to drive digital therapeutics adoption 199
15.3.7 REST OF EUROPE 203
15.4 ASIA PACIFIC 208
15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 209
15.4.2 CHINA 214
15.4.2.1 Software-driven therapeutics to gain regulatory momentum amid government digital health push 214
15.4.3 JAPAN 219
15.4.3.1 Demographic pressures and regulatory reform to drive cautious digital therapeutics adoption 219
15.4.4 INDIA 223
15.4.4.1 Regulatory formalization and selective capital deployment to shape early-stage growth 223
15.4.5 AUSTRALIA 228
15.4.5.1 Strong digital health ecosystem and telehealth adoption to drive digital therapeutics growth 228
15.4.6 SOUTH KOREA 232
15.4.6.1 Government digital health initiatives and AI innovation to accelerate digital therapeutics adoption 232
15.4.7 REST OF ASIA PACIFIC 237
15.5 LATIN AMERICA 241
15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 242
15.5.2 BRAZIL 246
15.5.2.1 Universal healthcare expansion and digital health innovation to drive digital therapeutics demand 246
15.5.3 MEXICO 250
15.5.3.1 Growing public health needs and expanding digital access to support market growth 250
15.5.4 REST OF LATIN AMERICA 255
15.6 MIDDLE EAST & AFRICA 259
15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 260
15.6.2 GCC COUNTRIES 264
15.6.2.1 National digital health guidance to accelerate software-based therapeutic adoption 264
15.6.2.2 Saudi Arabia 269
15.6.2.2.1 Vision 2030 digital health guidance to establish formal pathway for software-based therapeutics 269
15.6.2.3 UAE 274
15.6.2.3.1 Digital transformation and healthcare innovation to support digital therapeutics growth 274
15.6.2.4 Rest of Gcc Countries 278
15.6.3 SOUTH AFRICA 283
15.6.3.1 Digital health expansion and high disease burden to create opportunities for digital therapeutics 283
15.6.4 REST OF MIDDLE EAST & AFRICA 287
16 COMPETITIVE LANDSCAPE 293
16.1 OVERVIEW 293
16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 293
16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DIGITAL THERAPEUTICS MARKET 293
16.3 REVENUE ANALYSIS, 2021–2025 295
16.4 MARKET SHARE ANALYSIS, 2025 296
16.5 BRAND/PRODUCT COMPARISON 299
16.6 COMPANY VALUATION & FINANCIAL METRICS 300
16.6.1 FINANCIAL METRICS 300
16.6.2 COMPANY VALUATION 300
16.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 301
16.7.1 STARS 301
16.7.2 EMERGING LEADERS 301
16.7.3 PERVASIVE PLAYERS 301
16.7.4 PARTICIPANTS 302
16.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 303
16.7.5.1 Company footprint 303
16.7.5.2 Region footprint 304
16.7.5.3 Offering footprint 305
16.7.5.4 Application footprint 306
16.7.5.5 Revenue model footprint 307
16.7.5.6 End-user footprint 308
16.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 309
16.8.1 PROGRESSIVE COMPANIES 309
16.8.2 RESPONSIVE COMPANIES 309
16.8.3 DYNAMIC COMPANIES 309
16.8.4 STARTING BLOCKS 309
16.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 311
16.8.5.1 Detailed list of key startups/SMEs 311
16.8.5.2 Competitive benchmarking of startups/SMEs 311
16.9 COMPETITIVE SCENARIO 312
16.9.1 PRODUCT LAUNCHES & ENHANCEMENTS 312
16.9.2 DEALS 313
16.9.3 OTHER DEVELOPMENTS 314
17 COMPANY PROFILES 315
17.1 KEY PLAYERS 315
17.1.1 TELADOC HEALTH, INC. 315
17.1.1.1 Business overview 315
17.1.1.2 Products & services offered 316
17.1.1.3 Recent developments 317
17.1.1.3.1 Product launches & enhancements 317
17.1.1.3.2 Deals 318
17.1.1.4 MnM view 319
17.1.1.4.1 Right to win 319
17.1.1.4.2 Strategic choices 319
17.1.1.4.3 Weaknesses & competitive threats 319
17.1.2 NOOM, INC. 320
17.1.2.1 Business overview 320
17.1.2.2 Products & services offered 321
17.1.2.3 Recent developments 321
17.1.2.3.1 Product launches & enhancements 321
17.1.2.3.2 Deals 323
17.1.2.4 MnM view 324
17.1.2.4.1 Right to win 324
17.1.2.4.2 Strategic choices 324
17.1.2.4.3 Weaknesses & competitive threats 324
17.1.3 HINGE HEALTH, INC. 325
17.1.3.1 Business overview 325
17.1.3.2 Products & services offered 326
17.1.3.3 Recent developments 327
17.1.3.3.1 Product launches & enhancements 327
17.1.3.3.2 Deals 328
17.1.3.4 MnM view 329
17.1.3.4.1 Right to win 329
17.1.3.4.2 Strategic choices 329
17.1.3.4.3 Weaknesses & competitive threats 329
17.1.4 OMADA HEALTH INC. 330
17.1.4.1 Business overview 330
17.1.4.2 Products & services offered 331
17.1.4.3 Recent Developments 332
17.1.4.3.1 Product Launches & Enhancements 332
17.1.4.3.2 Deals 333
17.1.4.4 MnM view 334
17.1.4.4.1 Right to win 334
17.1.4.4.2 Strategic choices 334
17.1.4.4.3 Weaknesses & competitive threats 334
17.1.5 DARIOHEALTH CORP. 335
17.1.5.1 Business overview 335
17.1.5.2 Products & services offered 336
17.1.5.3 Recent developments 337
17.1.5.3.1 Product launches & enhancements 337
17.1.5.3.2 Deals 338
17.1.5.4 MnM view 338
17.1.5.4.1 Right to win 338
17.1.5.4.2 Strategic choices 339
17.1.5.4.3 Weaknesses & competitive threats 339
17.1.6 SWORD HEALTH, INC. 340
17.1.6.1 Business overview 340
17.1.6.2 Products & services offered 341
17.1.6.3 Recent developments 342
17.1.6.3.1 Product launches & enhancements 342
17.1.6.3.2 Deals 342
17.1.7 RESMED 344
17.1.7.1 Business overview 344
17.1.7.2 Products & services offered 345
17.1.7.3 Recent developments 346
17.1.7.3.1 Deals 346
17.1.8 VIRTA HEALTH CORP. 347
17.1.8.1 Business overview 347
17.1.8.2 Products & services offered 348
17.1.8.3 Recent developments 349
17.1.8.3.1 Product launches & enhancements 349
17.1.8.3.2 Deals 349
17.1.9 WELLDOC, INC. 350
17.1.9.1 Business overview 350
17.1.9.2 Products & services offered 351
17.1.9.3 Recent developments 351
17.1.9.3.1 Product launches & enhancements 351
17.1.9.3.2 Deals 352
17.1.10 CLICK THERAPEUTICS, INC. 354
17.1.10.1 Business overview 354
17.1.10.2 Products & services offered 355
17.1.10.3 Recent developments 356
17.1.10.3.1 Product launches & enhancements 356
17.1.10.3.2 Deals 357
17.1.10.3.3 Other developments 358
17.1.11 SIDEKICK HEALTH 359
17.1.11.1 Business overview 359
17.1.11.2 Products & services offered 359
17.1.11.3 Recent developments 361
17.1.11.3.1 Product launches & enhancements 361
17.1.11.3.2 Deals 362
17.1.12 AKILI, INC. 363
17.1.12.1 Business overview 363
17.1.12.2 Products & services offered 364
17.1.13 APPLIEDVR, INC. 365
17.1.13.1 Business overview 365
17.1.13.2 Products & services offered 366
17.1.13.3 Recent developments 366
17.1.13.3.1 Deals 366
17.1.14 WELLTHY THERAPEUTICS PVT. LTD. 367
17.1.14.1 Business overview 367
17.1.14.2 Products & services offered 368
17.1.15 HEADSPACE INC. 369
17.1.15.1 Business overview 369
17.1.15.2 Products & services offered 370
17.1.15.2.1 Product launches & enhancements 371
17.1.16 LARK TECHNOLOGIES, INC. 372
17.1.16.1 Business overview 372
17.1.16.2 Products & services offered 372
17.1.17 XRHEALTH 374
17.1.17.1 Business overview 374
17.1.17.2 Products & services offered 374
17.1.17.3 Recent developments 376
17.1.17.3.1 Product launches 376
17.1.17.3.2 Deals 376
17.1.18 AMALGAM RX, INC. 378
17.1.18.1 Business overview 378
17.1.18.2 Products & services offered 379
17.1.18.3 Recent developments 379
17.1.18.3.1 Deals 379
17.1.19 APTAR DIGITAL HEALTH 380
17.1.19.1 Business overview 380
17.1.19.2 Products & services offered 382
17.1.19.3 Recent developments 382
17.1.19.3.1 Deals 382
17.1.20 CANARY HEALTH 384
17.1.20.1 Business overview 384
17.1.20.2 Products & services offered 384
17.1.20.3 Recent developments 385
17.1.20.3.1 Deals 385
17.2 START-UP/SME PLAYERS 386
17.2.1 FREESPIRA 386
17.2.2 MINDABLE HEALTH GMBH 387
17.2.3 GET.ON INSTITUT FÜR ONLINE GESUNDHEITSTRAININGS GMBH 388
17.2.4 COGNIFIT INC. 389
17.2.5 2MORROW INC. 390
18 RESEARCH METHODOLOGY 391
18.1 RESEARCH APPROACH 391
18.1.1 SECONDARY RESEARCH 392
18.1.1.1 Key data from secondary sources 393
18.1.2 PRIMARY RESEARCH 393
18.1.2.1 Primary sources 394
18.1.2.2 Key data from primary sources 395
18.1.2.3 Breakdown of primaries 395
18.1.2.4 Insights from primary experts 396
18.2 RESEARCH METHODOLOGY DESIGN 396
18.3 MARKET SIZE ESTIMATION 398
18.4 DATA TRIANGULATION 403
18.5 MARKET SHARE ESTIMATION 404
18.6 STUDY ASSUMPTIONS 404
18.7 RESEARCH LIMITATIONS 405
18.7.1 METHODOLOGY-RELATED LIMITATIONS 405
18.8 RISK ASSESSMENT 405
19 APPENDIX 406
19.1 DISCUSSION GUIDE 406
19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 411
19.3 CUSTOMIZATION OPTIONS 413
19.4 RELATED REPORTS 413
19.5 AUTHOR DETAILS 414
圖表清單 List of Tables & Figures
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 39
TABLE 2 DIGITAL THERAPEUTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 62
TABLE 3 DIGITAL THERAPEUTICS MARKET: ROLE IN ECOSYSTEM 67
TABLE 4 INDICATIVE PRICING FOR DIGITAL THERAPEUTICS SOLUTIONS,
BY OFFERING (2025) 69
TABLE 5 INDICATIVE PRICING FOR DIGITAL THERAPEUTICS SOLUTIONS, BY REGION (2025) 69
TABLE 6 DIGITAL THERAPEUTICS MARKET: KEY CONFERENCES & EVENTS 2026–2027 70
TABLE 7 CASE 1: DIGITAL THERAPEUTICS FOR IMPROVING BALANCE AND
REDUCING FALL RISK 72
TABLE 8 CASE 2: DIGITAL THERAPEUTICS FOR WEIGHT MANAGEMENT
AND BEHAVIOR CHANGE 73
TABLE 9 CASE 3: PRESCRIPTION DIGITAL THERAPEUTICS FOR SCHIZOPHRENIA MANAGEMENT 73
TABLE 10 US-ADJUSTED RECIPROCAL TARIFF RATES 74
TABLE 11 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR DIGITAL THERAPEUTICS MARKET 83
TABLE 12 DIGITAL THERAPEUTICS MARKET: LIST OF PATENTS/PATENT APPLICATIONS 85
TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 94
TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 94
TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 95
TABLE 16 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 96
TABLE 17 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 96
TABLE 18 REGULATORY SCENARIO OF NORTH AMERICA 97
TABLE 19 REGULATORY SCENARIO OF EUROPE 97
TABLE 20 REGULATORY SCENARIO OF ASIA PACIFIC 98
TABLE 21 REGULATORY SCENARIO OF LATIN AMERICA 98
TABLE 22 REGULATORY SCENARIO OF MIDDLE EAST & AFRICA 99
TABLE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF
TOP THREE END USERS (%) 102
TABLE 24 KEY BUYING CRITERIA FOR TOP THREE END USERS 103
TABLE 25 UNMET NEEDS IN DIGITAL THERAPEUTICS MARKET 105
TABLE 26 END-USER EXPECTATIONS IN THE DIGITAL THERAPEUTICS MARKET 106
TABLE 27 DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 109
TABLE 28 DIGITAL THERAPEUTICS MARKET FOR SOFTWARE/PLATFORMS, BY REGION, 2024–2031 (USD MILLION) 110
TABLE 29 DIGITAL THERAPEUTICS MARKET FOR THERAPEUTIC PROGRAMS, BY REGION, 2024–2031 (USD MILLION) 112
TABLE 30 DIGITAL THERAPEUTICS MARKET FOR IMMERSIVE & INTERFACE-BASED THERAPEUTICS, BY REGION, 2024–2031 (USD MILLION) 113
TABLE 31 DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 115
TABLE 32 PRESCRIPTION DIGITAL THERAPEUTICS MARKET, BY REGION,
2024–2031 (USD MILLION) 116
TABLE 33 NON-PRESCRIPTION DIGITAL THERAPEUTICS MARKET, BY REGION,
2024–2031 (USD MILLION) 117
TABLE 34 DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 119
TABLE 35 DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 120
TABLE 36 DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 121
TABLE 37 DIGITAL THERAPEUTICS MARKET FOR DIABETES, BY REGION,
2024–2031 (USD MILLION) 122
TABLE 38 DIGITAL THERAPEUTICS MARKET FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS, BY REGION, 2024–2031 (USD MILLION) 123
TABLE 39 DIGITAL THERAPEUTICS MARKET FOR SMOKING CESSATION, BY REGION,
2024–2031 (USD MILLION) 124
TABLE 40 DIGITAL THERAPEUTICS MARKET FOR CHRONIC RESPIRATORY DISEASES,
BY REGION, 2024–2031 (USD MILLION) 125
TABLE 41 DIGITAL THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS,
BY REGION, 2024–2031 (USD MILLION) 126
TABLE 42 DIGITAL THERAPEUTICS MARKET FOR CARDIOVASCULAR DISORDERS,
BY REGION, 2024–2031 (USD MILLION) 127
TABLE 43 DIGITAL THERAPEUTICS MARKET FOR MEDICATION ADHERENCE, BY REGION, 2024–2031 (USD MILLION) 128
TABLE 44 DIGITAL THERAPEUTICS MARKET FOR SLEEP DISORDERS, BY REGION,
2024–2031 (USD MILLION) 129
TABLE 45 DIGITAL THERAPEUTICS MARKET FOR REHABILITATION & PATIENT CARE,
BY REGION, 2024–2031 (USD MILLION) 130
TABLE 46 DIGITAL THERAPEUTICS MARKET FOR SUBSTANCE USE DISORDERS & ADDICTION MANAGEMENT, BY REGION, 2024–2031 (USD MILLION) 131
TABLE 47 DIGITAL THERAPEUTICS MARKET FOR OTHER TREATMENT & CARE-RELATED APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 132
TABLE 48 DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 133
TABLE 49 DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 133
TABLE 50 DIGITAL THERAPEUTICS MARKET FOR PREDIABETES, BY REGION,
2024–2031 (USD MILLION) 134
TABLE 51 DIGITAL THERAPEUTICS MARKET FOR OBESITY & WEIGHT MANAGEMENT,
BY REGION, 2024–2031 (USD MILLION) 135
TABLE 52 DIGITAL THERAPEUTICS MARKET FOR NUTRITION & LIFESTYLE MANAGEMENT,
BY REGION, 2024–2031 (USD MILLION) 136
TABLE 53 DIGITAL THERAPEUTICS MARKET FOR OTHER PREVENTIVE APPLICATIONS,
BY REGION, 2024–2031 (USD MILLION) 137
TABLE 54 DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL,
2024–2031 (USD MILLION) 139
TABLE 55 DIGITAL THERAPEUTICS MARKET FOR SUBSCRIPTION-BASED MODELS, BY REGION, 2024–2031 (USD MILLION) 140
TABLE 56 DIGITAL THERAPEUTICS MARKET FOR LICENSING (ENTERPRISE/SAAS) MODELS, BY REGION, 2024–2031 (USD MILLION) 141
TABLE 57 DIGITAL THERAPEUTICS MARKET FOR OUTCOME-/VALUE-BASED MODELS,
BY REGION, 2024–2031 (USD MILLION) 142
TABLE 58 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024–2031 (USD MILLION) 144
TABLE 59 DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNELS, BY REGION,
2024–2031 (USD MILLION) 145
TABLE 60 DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNELS, BY REGION,
2024–2031 (USD MILLION) 146
TABLE 61 DIGITAL THERAPEUTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 148
TABLE 62 DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE,
2024–2031 (USD MILLION) 149
TABLE 63 DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2024–2031 (USD MILLION) 149
TABLE 64 DIGITAL THERAPEUTICS MARKET FOR HOSPITALS, BY REGION,
2024–2031 (USD MILLION) 150
TABLE 65 DIGITAL THERAPEUTICS MARKET FOR SPECIALTY CLINICS, BY REGION,
2024–2031 (USD MILLION) 151
TABLE 66 DIGITAL THERAPEUTICS MARKET FOR DIAGNOSTIC & REHABILITATION CENTERS, BY REGION, 2024–2031 (USD MILLION) 152
TABLE 67 DIGITAL THERAPEUTICS MARKET FOR OTHER HEALTHCARE PROVIDERS,
BY REGION, 2024–2031 (USD MILLION) 153
TABLE 68 DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE,
2024–2031 (USD MILLION) 154
TABLE 69 DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY REGION,
2024–2031 (USD MILLION) 154
TABLE 70 DIGITAL THERAPEUTICS MARKET FOR PUBLIC PAYERS, BY REGION,
2024–2031 (USD MILLION) 155
TABLE 71 DIGITAL THERAPEUTICS MARKET FOR PRIVATE PAYERS, BY REGION,
2024–2031 (USD MILLION) 156
TABLE 72 DIGITAL THERAPEUTICS FOR EMPLOYERS, BY REGION, 2024–2031 (USD MILLION) 157
TABLE 73 DIGITAL THERAPEUTICS FOR PATIENTS/INDIVIDUALS, BY REGION,
2024–2031 (USD MILLION) 158
TABLE 74 DIGITAL THERAPEUTICS FOR OTHER END USERS, BY REGION,
2024–2031 (USD MILLION) 159
TABLE 75 DIGITAL THERAPEUTICS MARKET, BY REGION, 2024–2031 (USD MILLION) 161
TABLE 76 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 163
TABLE 77 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 163
TABLE 78 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 163
TABLE 79 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 164
TABLE 80 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 164
TABLE 81 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 165
TABLE 82 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL,
2024–2031 (USD MILLION) 165
TABLE 83 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2024–2031 (USD MILLION) 165
TABLE 84 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 166
TABLE 85 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 166
TABLE 86 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS,
BY TYPE, 2024–2031 (USD MILLION) 167
TABLE 87 US: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 168
TABLE 88 US: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 168
TABLE 89 US: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 168
TABLE 90 US: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 169
TABLE 91 US: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 170
TABLE 92 US: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL,
2024–2031 (USD MILLION) 170
TABLE 93 US: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2024–2031 (USD MILLION) 170
TABLE 94 US: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 171
TABLE 95 US: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 171
TABLE 96 US: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE,
2024–2031 (USD MILLION) 171
TABLE 97 CANADA: DIGITAL THERAPEUTICS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 172
TABLE 98 CANADA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 173
TABLE 99 CANADA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 173
TABLE 100 CANADA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 174
TABLE 101 CANADA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS,
BY TYPE, 2024–2031 (USD MILLION) 174
TABLE 102 CANADA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL,
2024–2031 (USD MILLION) 175
TABLE 103 CANADA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2024–2031 (USD MILLION) 175
TABLE 104 CANADA: DIGITAL THERAPEUTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 175
TABLE 105 CANADA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS,
BY TYPE, 2024–2031 (USD MILLION) 176
TABLE 106 CANADA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS,
BY TYPE, 2024–2031 (USD MILLION) 176
TABLE 107 EUROPE: DIGITAL THERAPEUTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 177
TABLE 108 EUROPE: DIGITAL THERAPEUTICS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 178
TABLE 109 EUROPE: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 178
TABLE 110 EUROPE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 178
TABLE 111 EUROPE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 179
TABLE 112 EUROPE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS,
BY TYPE, 2024–2031 (USD MILLION) 179
TABLE 113 EUROPE: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL,
2024–2031 (USD MILLION) 180
TABLE 114 EUROPE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2024–2031 (USD MILLION) 180
TABLE 115 EUROPE: DIGITAL THERAPEUTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 180
TABLE 116 EUROPE: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS,
BY TYPE, 2024–2031 (USD MILLION) 181
TABLE 117 EUROPE: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 181
TABLE 118 GERMANY: DIGITAL THERAPEUTICS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 182
TABLE 119 GERMANY: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 182
TABLE 120 GERMANY: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 183
TABLE 121 GERMANY: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 183
TABLE 122 GERMANY: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS,
BY TYPE, 2024–2031 (USD MILLION) 184
TABLE 123 GERMANY: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL,
2024–2031 (USD MILLION) 184
TABLE 124 GERMANY: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2024–2031 (USD MILLION) 184
TABLE 125 GERMANY: DIGITAL THERAPEUTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 185
TABLE 126 GERMANY: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS,
BY TYPE, 2024–2031 (USD MILLION) 185
TABLE 127 GERMANY: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS,
BY TYPE, 2024–2031 (USD MILLION) 185
TABLE 128 FRANCE: DIGITAL THERAPEUTICS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 186
TABLE 129 FRANCE: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 187
TABLE 130 FRANCE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 187
TABLE 131 FRANCE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 188
TABLE 132 FRANCE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS,
BY TYPE, 2024–2031 (USD MILLION) 188
TABLE 133 FRANCE: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL,
2024–2031 (USD MILLION) 189
TABLE 134 FRANCE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2024–2031 (USD MILLION) 189
TABLE 135 FRANCE: DIGITAL THERAPEUTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 189
TABLE 136 FRANCE: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS,
BY TYPE, 2024–2031 (USD MILLION) 190
TABLE 137 FRANCE: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 190
TABLE 138 UK: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 191
TABLE 139 UK: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 191
TABLE 140 UK: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 192
TABLE 141 UK: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 192
TABLE 142 UK: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 193
TABLE 143 UK: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL,
2024–2031 (USD MILLION) 193
TABLE 144 UK: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2024–2031 (USD MILLION) 193
TABLE 145 UK: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 194
TABLE 146 UK: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 194
TABLE 147 UK: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS,
BY TYPE, 2024–2031 (USD MILLION) 194
TABLE 148 ITALY: DIGITAL THERAPEUTICS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 195
TABLE 149 ITALY: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 196
TABLE 150 ITALY: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 196
TABLE 151 ITALY: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 197
TABLE 152 ITALY: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 197
TABLE 153 ITALY: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL,
2024–2031 (USD MILLION) 198
TABLE 154 ITALY: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2024–2031 (USD MILLION) 198
TABLE 155 ITALY: DIGITAL THERAPEUTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 198
TABLE 156 ITALY: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 199
TABLE 157 ITALY: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 199
TABLE 158 SPAIN: DIGITAL THERAPEUTICS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 200
TABLE 159 SPAIN: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 200
TABLE 160 SPAIN: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 200
TABLE 161 SPAIN: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 201
TABLE 162 SPAIN: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 201
TABLE 163 SPAIN: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL,
2024–2031 (USD MILLION) 202
TABLE 164 SPAIN: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2024–2031 (USD MILLION) 202
TABLE 165 SPAIN: DIGITAL THERAPEUTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 202
TABLE 166 SPAIN: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 203
TABLE 167 SPAIN: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 203
TABLE 168 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 204
TABLE 169 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 204
TABLE 170 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 205
TABLE 171 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 205
TABLE 172 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 206
TABLE 173 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL,
2024–2031 (USD MILLION) 206
TABLE 174 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2024–2031 (USD MILLION) 206
TABLE 175 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 207
TABLE 176 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 207
TABLE 177 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS,
BY TYPE, 2024–2031 (USD MILLION) 208
TABLE 178 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 210
TABLE 179 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 210
TABLE 180 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 211
TABLE 181 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 211
TABLE 182 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 212
TABLE 183 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 212
TABLE 184 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL,
2024–2031 (USD MILLION) 213
TABLE 185 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2024–2031 (USD MILLION) 213
TABLE 186 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 213
TABLE 187 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS,
BY TYPE, 2024–2031 (USD MILLION) 214
TABLE 188 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS,
BY TYPE, 2024–2031 (USD MILLION) 214
TABLE 189 CHINA: DIGITAL THERAPEUTICS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 215
TABLE 190 CHINA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 215
TABLE 191 CHINA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 216
TABLE 192 CHINA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 216
TABLE 193 CHINA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS,
BY TYPE, 2024–2031 (USD MILLION) 217
TABLE 194 CHINA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL,
2024–2031 (USD MILLION) 217
TABLE 195 CHINA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2024–2031 (USD MILLION) 217
TABLE 196 CHINA: DIGITAL THERAPEUTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 218
TABLE 197 CHINA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 218
TABLE 198 CHINA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 218
TABLE 199 JAPAN: DIGITAL THERAPEUTICS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 219
TABLE 200 JAPAN: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 220
TABLE 201 JAPAN: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 220
TABLE 202 JAPAN: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 221
TABLE 203 JAPAN: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS,
BY TYPE, 2024–2031 (USD MILLION) 221
TABLE 204 JAPAN: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL,
2024–2031 (USD MILLION) 222
TABLE 205 JAPAN: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2024–2031 (USD MILLION) 222
TABLE 206 JAPAN: DIGITAL THERAPEUTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 222
TABLE 207 JAPAN: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 223
TABLE 208 JAPAN: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 223
TABLE 209 INDIA: DIGITAL THERAPEUTICS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 224
TABLE 210 INDIA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 224
TABLE 211 INDIA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 225
TABLE 212 INDIA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 225
TABLE 213 INDIA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 226
TABLE 214 INDIA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL,
2024–2031 (USD MILLION) 226
TABLE 215 INDIA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2024–2031 (USD MILLION) 226
TABLE 216 INDIA: DIGITAL THERAPEUTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 227
TABLE 217 INDIA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 227
TABLE 218 INDIA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 227
TABLE 219 AUSTRALIA: DIGITAL THERAPEUTICS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 228
TABLE 220 AUSTRALIA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 229
TABLE 221 AUSTRALIA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 229
TABLE 222 AUSTRALIA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 230
TABLE 223 AUSTRALIA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS,
BY TYPE, 2024–2031 (USD MILLION) 230
TABLE 224 AUSTRALIA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL,
2024–2031 (USD MILLION) 231
TABLE 225 AUSTRALIA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2024–2031 (USD MILLION) 231
TABLE 226 AUSTRALIA: DIGITAL THERAPEUTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 231
TABLE 227 AUSTRALIA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS,
BY TYPE, 2024–2031 (USD MILLION) 232
TABLE 228 AUSTRALIA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 232
TABLE 229 SOUTH KOREA: DIGITAL THERAPEUTICS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 233
TABLE 230 SOUTH KOREA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 233
TABLE 231 SOUTH KOREA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 234
TABLE 232 SOUTH KOREA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 234
TABLE 233 SOUTH KOREA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 235
TABLE 234 SOUTH KOREA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL,
2024–2031 (USD MILLION) 235
TABLE 235 SOUTH KOREA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2024–2031 (USD MILLION) 235
TABLE 236 SOUTH KOREA: DIGITAL THERAPEUTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 236
TABLE 237 SOUTH KOREA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 236
TABLE 238 SOUTH KOREA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS,
BY TYPE, 2024–2031 (USD MILLION) 237
TABLE 239 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 238
TABLE 240 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 238
TABLE 241 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 238
TABLE 242 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 239
TABLE 243 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 239
TABLE 244 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 240
TABLE 245 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024–2031 (USD MILLION) 240
TABLE 246 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 240
TABLE 247 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 241
TABLE 248 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 241
TABLE 249 LATIN AMERICA: DIGITAL THERAPEUTUCS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 242
TABLE 250 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 243
TABLE 251 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 243
TABLE 252 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 243
TABLE 253 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 244
TABLE 254 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 244
TABLE 255 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL,
2024–2031 (USD MILLION) 245
TABLE 256 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2024–2031 (USD MILLION) 245
TABLE 257 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 245
TABLE 258 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 246
TABLE 259 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS,
BY TYPE, 2024–2031 (USD MILLION) 246
TABLE 260 BRAZIL: DIGITAL THERAPEUTICS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 247
TABLE 261 BRAZIL: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 247
TABLE 262 BRAZIL: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 247
TABLE 263 BRAZIL: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 248
TABLE 264 BRAZIL: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS,
BY TYPE, 2024–2031 (USD MILLION) 248
TABLE 265 BRAZIL: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL,
2024–2031 (USD MILLION) 249
TABLE 266 BRAZIL: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2024–2031 (USD MILLION) 249
TABLE 267 BRAZIL: DIGITAL THERAPEUTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 249
TABLE 268 BRAZIL: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS,
BY TYPE, 2024–2031 (USD MILLION) 250
TABLE 269 BRAZIL: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS,
BY TYPE, 2024–2031 (USD MILLION) 250
TABLE 270 MEXICO: DIGITAL THERAPEUTICS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 251
TABLE 271 MEXICO: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 251
TABLE 272 MEXICO: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 252
TABLE 273 MEXICO: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 252
TABLE 274 MEXICO: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS,
BY TYPE, 2024–2031 (USD MILLION) 253
TABLE 275 MEXICO: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL,
2024–2031 (USD MILLION) 253
TABLE 276 MEXICO: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2024–2031 (USD MILLION) 253
TABLE 277 MEXICO: DIGITAL THERAPEUTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 254
TABLE 278 MEXICO: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 254
TABLE 279 MEXICO: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 254
TABLE 280 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 255
TABLE 281 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 256
TABLE 282 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 256
TABLE 283 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 257
TABLE 284 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 257
TABLE 285 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 258
TABLE 286 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024–2031 (USD MILLION) 258
TABLE 287 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 258
TABLE 288 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 259
TABLE 289 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 259
TABLE 290 MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 260
TABLE 291 MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 261
TABLE 292 MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 261
TABLE 293 MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 261
TABLE 294 MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 262
TABLE 295 MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 262
TABLE 296 MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 263
TABLE 297 MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024–2031 (USD MILLION) 263
TABLE 298 MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 263
TABLE 299 MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 264
TABLE 300 MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 264
TABLE 301 GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 265
TABLE 302 GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 266
TABLE 303 GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 266
TABLE 304 GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 266
TABLE 305 GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 267
TABLE 306 GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 267
TABLE 307 GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL,
2024–2031 (USD MILLION) 268
TABLE 308 GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2024–2031 (USD MILLION) 268
TABLE 309 GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 268
TABLE 310 GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 269
TABLE 311 GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS,
BY TYPE, 2024–2031 (USD MILLION) 269
TABLE 312 SAUDI ARABIA: DIGITAL THERAPEUTICS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 270
TABLE 313 SAUDI ARABIA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 270
TABLE 314 SAUDI ARABIA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 271
TABLE 315 SAUDI ARABIA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 271
TABLE 316 SAUDI ARABIA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 272
TABLE 317 SAUDI ARABIA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL,
2024–2031 (USD MILLION) 272
TABLE 318 SAUDI ARABIA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2024–2031 (USD MILLION) 272
TABLE 319 SAUDI ARABIA: DIGITAL THERAPEUTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 273
TABLE 320 SAUDI ARABIA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS,
BY TYPE, 2024–2031 (USD MILLION) 273
TABLE 321 SAUDI ARABIA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS,
BY TYPE, 2024–2031 (USD MILLION) 274
TABLE 322 UAE: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 275
TABLE 323 UAE: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 275
TABLE 324 UAE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 275
TABLE 325 UAE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT &
CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 276
TABLE 326 UAE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 276
TABLE 327 UAE: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL,
2024–2031 (USD MILLION) 277
TABLE 328 UAE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2024–2031 (USD MILLION) 277
TABLE 329 UAE: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 277
TABLE 330 UAE: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 278
TABLE 331 UAE: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE,
2024–2031 (USD MILLION) 278
TABLE 332 REST OF GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 279
TABLE 333 REST OF GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 279
TABLE 334 REST OF GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 280
TABLE 335 REST OF GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 280
TABLE 336 REST OF GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 281
TABLE 337 REST OF GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 281
TABLE 338 REST OF GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024–2031 (USD MILLION) 281
TABLE 339 REST OF GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 282
TABLE 340 REST OF GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 282
TABLE 341 REST OF GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 283
TABLE 342 SOUTH AFRICA: DIGITAL THERAPEUTICS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 284
TABLE 343 SOUTH AFRICA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 284
TABLE 344 SOUTH AFRICA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 284
TABLE 345 SOUTH AFRICA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 285
TABLE 346 SOUTH AFRICA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 285
TABLE 347 SOUTH AFRICA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL,
2024–2031 (USD MILLION) 286
TABLE 348 SOUTH AFRICA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2024–2031 (USD MILLION) 286
TABLE 349 SOUTH AFRICA: DIGITAL THERAPEUTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 286
TABLE 350 SOUTH AFRICA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 287
TABLE 351 SOUTH AFRICA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS,
BY TYPE, 2024–2031 (USD MILLION) 287
TABLE 352 REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 288
TABLE 353 REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 288
TABLE 354 REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 289
TABLE 355 REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE,
2024–2031 (USD MILLION) 289
TABLE 356 REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 290
TABLE 357 REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 290
TABLE 358 REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024–2031 (USD MILLION) 290
TABLE 359 REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET,
BY END USER, 2024–2031 (USD MILLION) 291
TABLE 360 REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 291
TABLE 361 REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 292
TABLE 362 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DIGITAL THERAPEUTICS MARKET, JANUARY 2023–JULY 2026 293
TABLE 363 DIGITAL THERAPEUTICS MARKET: DEGREE OF COMPETITION 297
TABLE 364 DIGITAL THERAPEUTICS MARKET: REGION FOOTPRINT 304
TABLE 365 DIGITAL THERAPEUTICS MARKET: OFFERING FOOTPRINT 305
TABLE 366 DIGITAL THERAPEUTICS MARKET: APPLICATION FOOTPRINT 306
TABLE 367 DIGITAL THERAPEUTICS MARKET: REVENUE MODEL FOOTPRINT 307
TABLE 368 DIGITAL THERAPEUTICS MARKET: END-USER FOOTPRINT 308
TABLE 369 DIGITAL THERAPEUTICS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 311
TABLE 370 DIGITAL THERAPEUTICS MARKET: COMPETITIVE BENCHMARKING
OF KEY EMERGING PLAYERS/STARTUPS, BY REGION 311
TABLE 371 DIGITAL THERAPEUTICS MARKET: COMPETITIVE BENCHMARKING
OF KEY EMERGING PLAYERS/STARTUPS, BY COMPONENT 312
TABLE 372 DIGITAL THERAPEUTICS MARKET: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023–JULY 2026 312
TABLE 373 DIGITAL THERAPEUTICS MARKET: DEALS, JANUARY 2023–JULY 2026 313
TABLE 374 DIGITAL THERAPEUTICS MARKET: OTHER DEVELOPMENTS,
JANUARY 2023–JULY 2026 314
TABLE 375 TELADOC HEALTH, INC.: COMPANY OVERVIEW 315
TABLE 376 TELADOC HEALTH, INC.: PRODUCTS & SERVICES OFFERED 316
TABLE 377 TELADOC HEALTH, INC.: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2023–JULY 2026 317
TABLE 378 TELADOC HEALTH, INC.: DEALS, JANUARY 2023−JULY 2026 318
TABLE 379 NOOM, INC.: COMPANY OVERVIEW 320
TABLE 380 NOOM, INC.: PRODUCTS & SERVICES OFFERED 321
TABLE 381 NOOM, INC.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023−JULY 2026 321
TABLE 382 NOOM, INC.: DEALS, JANUARY 2023−JULY 2026 323
TABLE 383 HINGE HEALTH, INC.: COMPANY OVERVIEW 325
TABLE 384 HINGE HEALTH, INC.: PRODUCTS & SERVICES OFFERED 326
TABLE 385 HINGE HEALTH, INC.: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2023−JULY 2026 327
TABLE 386 HINGE HEALTH, INC.: DEALS, JANUARY 2023−JULY 2026 328
TABLE 387 OMADA HEALTH INC.: COMPANY OVERVIEW 330
TABLE 388 OMADA HEALTH INC.: PRODUCTS & SERVICES OFFERED 331
TABLE 389 OMADA HEALTH INC.: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2023−JULY 2026 332
TABLE 390 OMADA HEALTH INC.: DEALS, JANUARY 2023−JULY 2026 333
TABLE 391 DARIOHEALTH CORP.: COMPANY OVERVIEW 335
TABLE 392 DARIOHEALTH CORP.: PRODUCTS & SERVICES OFFERED 336
TABLE 393 DARIOHEALTH CORP.: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2023−JULY 2026 337
TABLE 394 DARIOHEALTH CORP.: DEALS, JANUARY 2023−JULY 2026 338
TABLE 395 SWORD HEALTH, INC.: COMPANY OVERVIEW 340
TABLE 396 SWORD HEALTH, INC.: PRODUCTS & SERVICES OFFERED 341
TABLE 397 SWORD HEALTH, INC.: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2023−JUNE 2026 342
TABLE 398 SWORD HEALTH, INC.: DEALS, JANUARY 2023−JULY 2026 342
TABLE 399 RESMED: COMPANY OVERVIEW 344
TABLE 400 RESMED: PRODUCTS & SERVICES OFFERED 345
TABLE 401 RESMED: DEALS, JANUARY 2023−JULY 2026 346
TABLE 402 VIRTA HEALTH CORP.: COMPANY OVERVIEW 347
TABLE 403 VIRTA HEALTH CORP.: PRODUCTS & SERVICES OFFERED 348
TABLE 404 VIRTA HEALTH CORP.: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2023−JULY 2026 349
TABLE 405 VIRTA HEALTH CORP.: DEALS, JANUARY 2023−JULY 2026 349
TABLE 406 WELLDOC, INC.: COMPANY OVERVIEW 350
TABLE 407 WELLDOC, INC.: PRODUCTS & SERVICES OFFERED 351
TABLE 408 WELLDOC, INC.: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2023−JULY 2026 351
TABLE 409 WELLDOC, INC.: DEALS, JANUARY 2023−JULY 2026 352
TABLE 410 CLICK THERAPEUTICS, INC.: COMPANY OVERVIEW 354
TABLE 411 CLICK THERAPEUTICS, INC.: PRODUCTS & SERVICES OFFERED 355
TABLE 412 CLICK THERAPEUTICS, INC.: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2023−JULY 2026 356
TABLE 413 CLICK THERAPEUTICS, INC.: DEALS, JANUARY 2023−JULY 2026 357
TABLE 414 CLICK THERAPEUTICS, INC.: OTHER DEVELOPMENTS, JANUARY 2023−JUNE 2026 358
TABLE 415 SIDEKICK HEALTH: COMPANY OVERVIEW 359
TABLE 416 SIDEKICK HEALTH: PRODUCTS & SERVICES OFFERED 359
TABLE 417 SIDEKICK HEALTH: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2023−JULY 2026 361
TABLE 418 SIDEKICK HEALTH: DEALS, JANUARY 2023−JUNE 2026 362
TABLE 419 AKILI, INC.: COMPANY OVERVIEW 363
TABLE 420 AKILI, INC.: PRODUCTS & SERVICES OFFERED 364
TABLE 421 APPLIEDVR, INC.: COMPANY OVERVIEW 365
TABLE 422 APPLIEDVR, INC.: PRODUCTS & SERVICES OFFERED 366
TABLE 423 APPLIEDVR, INC.: DEALS, JANUARY 2023−JUNE 2026 366
TABLE 424 WELLTHY THERAPEUTICS PVT. LTD.: COMPANY OVERVIEW 367
TABLE 425 WELLTHY THERAPEUTICS PVT LTD: PRODUCTS & SERVICES OFFERED 368
TABLE 426 HEADSPACE INC.: COMPANY OVERVIEW 369
TABLE 427 HEADSPACE INC.: PRODUCTS & SERVICES OFFERED 370
TABLE 428 HEADSPACE INC.: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2023−JULY 2026 371
TABLE 429 LARK TECHNOLOGIES, INC.: COMPANY OVERVIEW 372
TABLE 430 LARK TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED 372
TABLE 431 XRHEALTH: COMPANY OVERVIEW 374
TABLE 432 XRHEALTH: PRODUCTS & SERVICES OFFERED 374
TABLE 433 XRHEALTH: PRODUCT LAUNCHES, JANUARY 2023−JULY 2026 376
TABLE 434 XRHEALTH: DEALS, JANUARY 2023−JULY 2026 376
TABLE 435 AMALGAM RX, INC.: COMPANY OVERVIEW 378
TABLE 436 AMALGAM RX, INC.: PRODUCTS & SERVICES OFFERED 379
TABLE 437 AMALGAM RX, INC.: DEALS, JANUARY 2023−JULY 2026 379
TABLE 438 APTAR DIGITAL HEALTH: COMPANY OVERVIEW 380
TABLE 439 APTAR DIGITAL HEALTH: PRODUCTS & SERVICES OFFERED 382
TABLE 440 APTAR DIGITAL HEALTH: DEALS, JANUARY 2023−JUNE 2026 382
TABLE 441 CANARY HEALTH: COMPANY OVERVIEW 384
TABLE 442 CANARY HEALTH: PRODUCTS & SERVICES OFFERED 384
TABLE 443 CANARY HEALTH: DEALS, JANUARY 2023−JUNE 2026 385
TABLE 444 RISK ASSESSMENT: DIGITAL THERAPEUTICS MARKET 405
FIGURE 1 DIGITAL THERAPEUTICS MARKET SEGMENTATION & REGIONAL SCOPE 37
FIGURE 2 MARKET SCENARIO 42
FIGURE 3 GLOBAL DIGITAL THERAPEUTICS MARKET, 2024–2031 43
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN
DIGITAL THERAPEUTICS MARKET, 2023–2026 43
FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF DIGITAL THERAPEUTICS MARKET 44
FIGURE 6 HIGH-GROWTH SEGMENTS IN DIGITAL THERAPEUTICS MARKET, 2026–2031 45
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN DIGITAL THERAPEUTICS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 46
FIGURE 8 RISING DEMAND FOR DIGITAL HEALTHCARE AND PATIENT-CENTRIC CARE TO DRIVE GROWTH IN DIGITAL THERAPEUTICS MARKET 48
FIGURE 9 PRESCRIPTION DIGITAL THERAPEUTICS IN US ACCOUNTED FOR
LARGEST MARKET SHARE IN 2025 49
FIGURE 10 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 49
FIGURE 11 DIGITAL THERAPEUTICS MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 51
FIGURE 12 DIGITAL THERAPEUTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 61
FIGURE 13 DIGITAL THERAPEUTICS MARKET: VALUE CHAIN ANALYSIS 65
FIGURE 14 DIGITAL THERAPEUTICS MARKET: ECOSYSTEM ANALYSIS 67
FIGURE 15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 71
FIGURE 17 PATENT PUBLICATION TRENDS IN DIGITAL THERAPEUTICS MARKET, 2015–2026 82
FIGURE 18 JURISDICTION & TOP APPLICANT ANALYSIS FOR DIGITAL THERAPEUTICS MARKET 83
FIGURE 19 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR DIGITAL THERAPEUTICS MARKET (JANUARY 2015–JULY 2026) 84
FIGURE 20 MARKET POTENTIAL OF AI/GEN AI ON DIGITAL THERAPEUTICS ACROSS INDUSTRIES 88
FIGURE 21 IMPACT OF AI/GEN AI ON INTERCONNECTED & ADJACENT ECOSYSTEMS 90
FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS 102
FIGURE 23 KEY BUYING CRITERIA FOR TOP THREE END USERS 103
FIGURE 24 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET SNAPSHOT 162
FIGURE 25 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET SNAPSHOT 209
FIGURE 26 REVENUE ANALYSIS OF KEY PLAYERS IN DIGITAL THERAPEUTICS MARKET,
2021–2025 296
FIGURE 27 MARKET SHARE ANALYSIS OF KEY PLAYERS IN DIGITAL THERAPEUTICS MARKET (2025) 297
FIGURE 28 DIGITAL THERAPEUTICS MARKET: BRAND COMPARATIVE ANALYSIS 299
FIGURE 29 EV/EBITDA OF KEY VENDORS 300
FIGURE 30 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 300
FIGURE 31 DIGITAL THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2025 302
FIGURE 32 DIGITAL THERAPEUTICS MARKET: COMPANY FOOTPRINT 303
FIGURE 33 DIGITAL THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 310
FIGURE 34 TELADOC HEALTH, INC.: COMPANY SNAPSHOT (2025) 316
FIGURE 35 HINGE HEALTH, INC.: COMPANY SNAPSHOT (2025) 326
FIGURE 36 OMADA HEALTH INC.: COMPANY SNAPSHOT (2025) 331
FIGURE 37 DARIOHEALTH CORP.: COMPANY SNAPSHOT (2025) 336
FIGURE 38 RESMED: COMPANY SNAPSHOT (2025) 345
FIGURE 39 APTAR DIGITAL HEALTH: COMPANY SNAPSHOT (2025) 381
FIGURE 40 RESEARCH DESIGN 391
FIGURE 41 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 395
FIGURE 42 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 397
FIGURE 43 BOTTOM-UP APPROACH 398
FIGURE 44 TOP-DOWN APPROACH 399
FIGURE 45 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF DIGITAL THERAPEUTICS INDUSTRY 400
FIGURE 46 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 400
FIGURE 47 DATA TRIANGULATION METHODOLOGY 403
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們